| Bioactivity | Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. | ||||||||||||
| Invitro | Capecitabine is an anti-cancer chemotherapy drug. It is classified as an antimetabolite. Capecitabine is converted into 5′-deoxy-5-fluorocytidine (5′DFCR), 5′-deoxy-5-fluorouridine (5′DFUR) and 5-FU by carboxylesterases (CES1 and 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP), in both liver and tumour. Capecitabine induces a significant cytotoxic effect in vitro only at high concentrations. Mean IC50 values vary from 860 μM in COLO205 cells to 6000 μM in HCT8 cells[2]. | ||||||||||||
| Name | Capecitabine | ||||||||||||
| CAS | 154361-50-9 | ||||||||||||
| Formula | C15H22FN3O6 | ||||||||||||
| Molar Mass | 359.35 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|